TP53 and non-small cell lung carcinoma: These systems also lead to significant upregulation of p53 and downregulation of SIRT 1 in non-small cell lung cancer models, providing valuable insight into the therapeutic potential of hybrid polymeric systems that blend biodegradability with controlled release kinetics [135].